Skip to Content
Merck
  • Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Antimicrobial agents and chemotherapy (2008-03-12)
David L Wyles, Kelly A Kaihara, Robert T Schooley
ABSTRACT

Rapid emergence of resistance to monotherapy with virus-specific inhibitors necessitates combination therapy. ACH-806 is a hepatitis C virus NS4A inhibitor with a novel mechanism of action and resistance pathway. This compound was synergistic with NS3 protease inhibitors and NS5B nucleoside and nonnucleoside polymerase inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interferon-αA/D human, ≥95%, recombinant, expressed in E. coli, buffered aqueous solution, suitable for cell culture